Rift Valley Fever Virus: Molecular Biologic Studies of the M Segment RNA for Application in Disease Prevention.
Abstract
The coding capacity and expression strategy of the Rift Valley Fever Virus M segment were investigated in detail employing cell-free transcription-translation and recombinant vaccinia virus systems. The results indicate that the M segment encodes a primary translation product of 133 kd representing the entire large open reading frame (ORF), which is co-translationally processed. The processed products are the viral glycoproteins G2 and G1, and two newly characterized polypeptides: a glycosylated 78 kd protein, and a non-glycosylated 14 kd protein. The 78 kd protein initiates from the first ATG codon of the ORF and encompasses the entire pre-glycoprotein and glycoprotein G2 coding sequences. The 14 kd protein initiates at the second ATG and represents only pre-glycoprotein sequences. All of these M segment products are largely Golgi-localized in both RVFV-infected and recombinant vaccinia virus-infected cells. Important to expression and subcellular localization of the glycoproteins are the 22 hydrophobic amino acids directly preceding the mature glycoprotein coding sequences. This work demonstrates the utility of recombinant RVFV-vaccinia viruses are also viable live virus vaccine candidates. Work with these viruses has provided further support for the notion that in the RVF disease system, virus neutralization does not correlate with animal protection. Keywords: viral M segment RNA; cell-free transcription-translation: subunit immunogen; animal disease protection
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 1987
- Accession Number
- ADA186603
Entities
People
- Marc S. Collett